Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-08-16
2005-08-16
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100
Reexamination Certificate
active
06930175
ABSTRACT:
pp32 is a member of a highly conserved family of differentiation-regulated nuclear proteins that is highly expressed in nearly all human prostatic adenocarcinomas of Gleason Grade≧5. This contrasts with the low percentage of prostate tumors that express molecular alterations in proto-oncogens or demonstrate tumor suppressor mutation or loss of heterozygosity. By analysis of specimens of human prostatic adenocarcinoma and paired adjacent normal prostate from three individual patients, the inventors have shown that normal prostate continues to express normal pp32, whereas three of three sets of RT-PCR-amplified transcripts from prostatic adenocarcinomas display multiple cancer-associated coding sequence changes. The cancer-associated sequence changes appear to be functionally significant. Normal pp32 exerts antineoplastic effects through suppression of transformation. In contrast, cancer-associated pp32 variants augment, rather than inhibit, transformation.
REFERENCES:
patent: 4874845 (1989-10-01), Saito et al.
patent: 4889818 (1989-12-01), Gelfand et al.
patent: 5200313 (1993-04-01), Carrico
patent: 5527884 (1996-06-01), Russell et al.
patent: 5726018 (1998-03-01), Pasternack
patent: 5734022 (1998-03-01), Pasternack
patent: 5756676 (1998-05-01), Pasternack
patent: 5874234 (1999-02-01), Pasternack
patent: 6040173 (2000-03-01), Pasternack
patent: 2003/0129631 (2003-07-01), Pasternack et al.
patent: 0375408 (1990-06-01), None
patent: WO 92/02554 (1992-02-01), None
patent: 9403594 (1994-02-01), None
patent: 9610092 (1996-04-01), None
patent: WO 99/29906 (1999-06-01), None
Rebel, et al., “Human pp32 pseudogene,” Gen Bank Accession No. U71084, Apr. 3, 1997.
Kochevar, et al., “Homo sapienscandidate tumor suppressor pp32r1 (PP32R1) gene,” Gene Bank Accession No. AF008216, Feb. 5, 199.
Norbert Zilka et al., “A rapid immunohistochemical primary screening assay for hybridomas,” Journal of Immunological Methods 9223 (2002) pp. 1-5.
Geert Van Leenders et al., “Demonstration of Intermediate Cells during Human Prostate Epithelial Differentation In Situ and In Vitro Using Triple-Staining Confocal Scanning Microscopy,” Laboratory Investigation, Aug. 2000, vol. 80, No. 8, pp. 1251-1258.
Xiongwen Zhang et al., “Apoptosis induction in prostate cancer cells by a novel gene product, pHyde, involves caspase-3,” Oncogene (2000) 20, pp. 5982-5990.
Valerio Orlando, “Polycomb, Epigenomes, and Control of Cell Indentity,” Cell, vol. 112, pp. 599-606, Mar. 7, 2003.
Antoni Matilla et al., “The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1,”Nature, 389, pp. 818, 974-978, 604-607, 1997.
Asok Mukhopadhyay et al., “Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines,” Oncogene (2001) 20, 7597-7609.
Kazuo Oba et al., “Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer,” Cancer Genetics and Cytogenetics 124 (2001), pp. 20-26.
G. J. L. H. Van Leenders et al., “Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis,” BJU International (2001), 88(Suppl. 2), pp. 35-42.
Martin Radrizzani et al., “Differential expression of CPD1 during postnatal development in the mouse cerebellum,” Brain Research 907 (2001), pp. 162-174.
Mitchell S. Steiner et al., “Growth Inhibition of Prostate Cancer by an Adenovirus Expressing a Novel Tumor Suppressor Gene, pHyde1,” Cancer Research 60, pp. 4419-4425, Aug. 15, 2001.
Josephine N. Harada et al., “Analysis of the Adenovirus E1B-55K-Anchores Proteome Reveals Its Link to Ubiquitination Machinery,” Journal Of Virology, Sep. 2002, vol. 76, No. 18, pp. 9194-9206.
Monica Holmberg et al., Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions, Human Molecular Genetics, 1998, vol. 7, No. 5, pp. 913-918.
Xuejun Jiang et al., “Distinctive Roles of PHAP Proteins and Prothymosin-α in a Death Regulatory Pathway,” Science, vol. 299, Jan. 10, 2003, pp. 223-226.
M. Jiang et al., Molecular cloning and characterization of a novel human gene (ANP32E alias LANPL) from human fetal brain, Cytogenet Genome Res. 97:68-71 (2002).
Maarten R. Leerkes et al., “In Silico Comparsion of the Transcriptome Derived from Purified Normal Breast Cells and Breast Tumor Cell Lines Reveals Candidate Upregulated Genes in Breast Tumor Cells,” Genomics, vol. 79, No. 2, Feb. 2002, pp. 257-265.
Zusen Fan et al., “Tumor Suppressor NM23-H1 Is a Granzyme A-Activated Dnase during CTL-Mediated Apotosis, and the Nucleosome Assembly Protein SET Is Its Inhibitor,” Cell, vol. 112, pp. 659-672, Mar. 7, 2003.
Samer W. K. Al-Murrani et al., “Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun AND AP-1 activity,” Biochem. J. (1999) 341, pp. 293-298.
C. M. Brennan et al., “HuR and Mma stability,” CMLS Cell. Mol. Life Sci. 58 (2001), pp. 266-277.
Fusheng Li et al., Ataxin-3 Is a Histone-binding Protein with Two Independent Transcriptional Corepressor Acivities, The Journal Of Biological Chemistry, vol. 277, No. 47, Issue of Nov. 22, pp. 45004-45012, 2002.
Ji-Chun Xue et al., “Idenitification of a Novel Testis-Specific Leucine-Rich Protein in Humans and Mice,” Biology of Reproduction 62, pp. 1278-1284 (2000).
Kadkol et al., “Novel Nuclear Phosphoprotein pp32 Is Highly Expressed in Intermediate-and High-Grade Prostate Cancer,” The Prostate 34:231-237 (1998).
Chen et al., “Structure of pp32, an Acidic Nuclear Protein With Inhibits Oncogene-induced Formation of Transformed Foci,” Molecular Biology of the Cell, vol. 7, 2045-2046, Dec. 1996.
Parker et al., “Cancer Statistics, 1996,” CA, a Cancer Journal for Clinicians, 46:5-27, 1996.
Potosky et al., “The Role of Increasing Detection in the Rising Incidence of Prostate Cancer,” JAMA, 273(7)548-552, 1995.
Fleming et al., “Expression of the c-myc Protooncogene in Human Prostatic Carcinoma and Benign Prostatic Hyperplasia,” Cancer Research, 46:1535-1538, 1986.
Visakorpi et al., “Genetic Changes in Primary and Recurrent Prostate Cancer by Comparative Genomic Hybridization,” Cancer Research, 55:342-347, 1995.
Gusev et al., “pp32 overexpression induces nuclear pleomorphism in rat prostatic carcinoma cells,” Cell Proliferation, 29:643-653, 1996, Blackwell Science, Ltd.
Walensky et al., “A Novel M, 32,000 Nuclear Phosphoprotein Is Selectively Expressed in Cells Competent for Self-Renewal,” Cancer Research, 53:4720-4726, 1993.
Vaesen et al., “Purification and Characterization of Two Putative HLA Class II Associated Protein: PHAPI and PHAPII,” Biol. Chem. Hoppe-Seyler, 375:113-126, 1994, Walter de Gruyter & Co.
Fink et al., “Localization of the Gene Encoding the Putative Human HLA Class II-Associated Protien (PHAPI) to Chromosome 15q22.3-q23 by Flurescence in Situ Hybridization,” Genomics, 29:309-310, 1995, Academic Press, Inc.
Li et al., “Molecular Identification of l1PP2A,a Novel Potent Heat-Stable Inhibitor Protien of Protein Phosphatase 2A,” Biochemistry, 35:6998-7002, 1996, American Chemical Society.
Ulitzur et al,. “Biochemical Characterization of Mapmodulin, a Protein That Binds Microtuble-associated Protiens, ” Journal o fBiological Chemistry, 272:30577-30582, 1997, The American Society for Biochemistry and Molecular Biology, Inc.
Matsuoka et al., “A nuclear factor containing the leucine-rich repeats expressed in murine cerebellar neurons,” Proc. Natl. Acad. Sci. USA, 91:9670-9674, 1994.
Mencinger et al., “Expression analysis and chromosomal mapping of a novel human gene, APRIL, encoding an acidic protein rich in leucines, ” Biochimica et Biophysica Acta., 1395:176-180, 1998, Elsevier Science B.V.
Malek et
Brody Jonathan R.
Kadkol Shrihari S.
Kocheavar Gerald J.
Pasternack Gary R.
Helms Larry R.
Hunton & Williams LLP
The Johns Hopkins University School of Medicine
Yu Misook
LandOfFree
Gene family with transformation modulating activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene family with transformation modulating activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene family with transformation modulating activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3523810